EAJF Stock Overview
A biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ValiRx plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.004 |
| 52 Week High | UK£0.07 |
| 52 Week Low | UK£0.004 |
| Beta | 0.56 |
| 1 Month Change | -74.19% |
| 3 Month Change | -76.47% |
| 1 Year Change | -93.94% |
| 3 Year Change | -99.18% |
| 5 Year Change | -84.00% |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| EAJF | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.6% | -2.0% |
| 1Y | -93.9% | -13.2% | 6.8% |
Return vs Industry: EAJF underperformed the German Biotechs industry which returned -13.2% over the past year.
Return vs Market: EAJF underperformed the German Market which returned 6.8% over the past year.
Price Volatility
| EAJF volatility | |
|---|---|
| EAJF Average Weekly Movement | 57.7% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EAJF's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: EAJF's weekly volatility has increased from 36% to 58% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 16 | n/a | www.valirx.com |
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells.
ValiRx plc Fundamentals Summary
| EAJF fundamental statistics | |
|---|---|
| Market cap | €1.16m |
| Earnings (TTM) | -€2.38m |
| Revenue (TTM) | €11.58k |
100.0x
P/S Ratio-0.5x
P/E RatioIs EAJF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EAJF income statement (TTM) | |
|---|---|
| Revenue | UK£9.60k |
| Cost of Revenue | UK£1.44k |
| Gross Profit | UK£8.16k |
| Other Expenses | UK£1.98m |
| Earnings | -UK£1.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.015 |
| Gross Margin | 85.00% |
| Net Profit Margin | -20,554.01% |
| Debt/Equity Ratio | 0.5% |
How did EAJF perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 00:26 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ValiRx plc is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Donnellan | Cavendish |
| Edward Jinks | Cavendish Historical (Cenkos Securities) |
| Vadim Alexandre Khalil | Daniel Stewart & Company |